纤维酸和选择性PPARα调制剂 (SPPARMα),纤维酸对KATP通道活性和胰岛素分泌的影响
Shigeki Kitamura1,2, Naoya Murao3, Shoko Yokota1
1Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
BMC research notes
|September 12, 2023
概括
纤维酸是一种PPARα连接体,通过关闭对ATP敏感的 (KATP) 通道来刺激胰岛素分泌. 然而,新的PPARα连接体pemafibrate不会影响胰岛素分泌或KATP通道活性.
科学领域:
- 内分泌学 在内分泌学.
- 分子药理学分子药理学
背景情况:
- 在胰腺β细胞中的ATP敏感 (KATP) 通道调节胰岛素分泌.
- 氧酶增殖器激活受体 (PPAR) α配体,如纤维酸,用于失脂症,可以影响KATP通道.
- 佩马菲布拉特是一种新型PPARα连接体,可能对葡萄糖代谢产生影响.
研究的目的:
- 为了研究PPARα连接体pemafibrate对胰岛素分泌和胰腺β细胞中的KATP通道的影响.
- 为了比较pemafibrate与 fenofibrate的作用,这是一个已知的KATP通道调节器.
主要方法:
- 在MIN6细胞中测量胰岛素分泌,使用在不同葡萄糖度下进行批次化.
- 使用全细胞补丁技术评估了KATP通道活性.
- 分析了胰岛素mRNA表达水平,用于纤维酸和纤维酸治疗.
主要成果:
- 费诺纤维酸 (100μM) 在低血糖条件下显著增加胰岛素分泌,并减少KATP通道电流.
- 在任何测试条件下,Pemafibrate (100μM) 并没有影响胰岛素分泌.
- 与芬诺纤维酸相反,纤维酸对KATP通道活性或胰岛素mRNA表达没有影响.
结论:
- 作为PPARα连接体的pemafibrate不调节KATP通道,也不刺激胰腺β细胞中的胰岛素分泌.
- 相比之下,纤维酸通过抑制KATP通道来增强胰岛素分泌.
- 这些发现区分了pemafibrate和 fenofibrate在胰岛素分泌调节方面的细胞机制.
相关概念视频
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
199
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
199


